Lupin Gains FDA Tentative Nod for COPD Generic, Targeting $261M Market
Event summary
- Lupin received tentative FDA approval for its generic version of Yupelri® Inhalation Solution for COPD treatment.
- The approved product is bioequivalent to Mylan's Yupelri®, with estimated U.S. sales of $260.7M annually (IQVIA MAT March 2026).
- Lupin's Revefenacin Inhalation Solution is indicated for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
- This marks Lupin's entry into the respiratory therapeutics market with a complex generic product.
The big picture
Lupin's FDA tentative approval for Revefenacin Inhalation Solution represents a strategic move into the high-value respiratory therapeutics market, targeting a product with significant revenue potential. This approval underscores Lupin's capability in developing complex generics, positioning the company to compete with established players like Mylan in the COPD treatment space. The approval also highlights the ongoing trend of generic drug manufacturers targeting lucrative branded respiratory medications as patents expire.
What we're watching
- Market Penetration
- How quickly Lupin can capture market share from Mylan's Yupelri® in the COPD treatment segment.
- Regulatory Clearance
- Whether the tentative approval will transition to full approval and the timeline for commercial launch.
- Competitive Response
- How Viatris (Mylan's parent company) may react to this generic competition in the respiratory therapeutics market.
Related topics